CD BioSciences Releases Insulin Signaling Pathway for Researchers
CD BioSciences introduces new insulin signaling pathways to the life science community for research uses.
- (1888PressRelease) April 30, 2022 - CD BioSciences, a US-based life science research product supplier and CRO, recently introduces new insulin signaling pathways to the life science community for research uses. These new signaling pathways in combination with other metabolic signaling pathways, such as TOR pathway, and AMPK pathway can cover all aspects of cell death study for researchers.
Metabolism describes the life-sustaining chemical reactions in an organism. It can be divided into two categories: catabolism, the breakdown of molecules, and anabolism, the synthesis of molecules. Metabolism is closely related to the availability of nutrients such as proteins, lipids and carbohydrates.
Metabolic pathways are a series of metabolic chemical reactions catalyzed by a series of enzymes. However, metabolic signaling pathways refer to cellular signaling that respond to metabolic states and regulate cellular events to maintain cellular and organismal homeostasis. Dysregulation of these pathways is associated with obesity, type 2 diabetes, and metabolic diseases such as cancer and aging.
Signaling pathways refer to the functional interdependence between different classes of molecules that together determine cellular responses and ultimately influence cell growth and survival based on extracellular signals. The study of signal transduction mechanism has always been the core of modern life science research.
The insulin signaling pathway is a signal transduction that regulates glucose homeostasis by controlling glucose and lipid metabolism. When insulin is released by pancreatic beta cells in response to elevated levels of nutrients, it binds to insulin receptors, activating signal transduction and leading to cellular processes that promote glucose, fatty acid, and amino acids. Insulin resistance, or the inability of cells to respond properly to insulin, is the underlying cause of type 2 diabetes, and it is also closely linked to neurodegenerative diseases such as Alzheimer's Disease, Parkinson's disease and Huntington's disease.
As a trusted CRO, CD BioSciences provides a comprehensive panel of solutions covering all aspects of life science research, including metabolism. Now CD BioSciences also offers insulin signaling pathways for scientific applications. "We're dedicated to meeting all of your signaling pathway research needs. Adding the insulin signaling pathways to our existing portfolio will help customers overcome life science challenges, enabling them to accelerate cell death study faster." said Kristy J. Morris, the marketing director at CD BioSciences.
CD BioSciences' solutions for metabolism research include but are not limited to Regulator Identification (identifying gene regulators participating in certain metabolic signaling pathways), Regulator Characterization (studying the molecular function of certain regulators in metabolic signaling pathways), Mechanism Study (investigating into the mechanism of regulation of certain regulators), and Phenotype Analysis (analyzing the cellular phenotypes regulated by genes/proteins of interest).
"Our solutions are designed to cover all aspects of signaling pathway research, developed and processed to the highest standards. Furthermore, we always deliver results on time without compromising quality." added Kristy.
Customers for more information about insulin signaling pathways, please visit CD BioSciences at https://www.cd-biosciences.com/.
About CD BioSciences
CD BioSciences is a trusted research product supplier and CRO based in New York. With high-quality reagents and comprehensive services, CD BioSciences is the one-stop shop devoted to researchers making advancements in signaling pathway studies.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam